West Pharmaceutical Services

West Pharmaceutical Services

Price: 330.92

Company and Business Model

West Pharmaceutical Services is a leading provider of innovative solutions for injectable drug delivery and containment. The company specializes in manufacturing components and systems for the pharmaceutical and biotechnology industries, including prefillable syringes, vials, and other packaging solutions. Major business segments include Pharmaceutical Packaging Systems and Contract Manufacturing. The primary revenue sources are sales of these products to pharmaceutical companies and contract services for drug development and manufacturing.

Investment Profile

The investment profile of West Pharmaceutical Services is more aligned with growth investors, given its focus on innovation and expanding market presence. The company demonstrates solid revenue growth and a relatively low dividend yield, indicating a reinvestment strategy. This profile may appeal to those seeking long-term capital appreciation rather than immediate income.

Official website

Fundamental metrics (experimental)

EPS (TTM) — earnings per share for the last 12 months, $
7.52 OK
Revenue QoQ — quarter-over-quarter revenue growth
5.0%
EPS surprise
26.8% better than expected
20d volatility
1.8% stable
Dividend yield
0.3% low last ex-date: 2026-04-29
FMP / FinFeed data updated: 2026-06-11
Reco: Buy Potential: 74 Risk: 31 Updated: 2026-06-11 05:37
How recommendation works
Why AI thinks so:
Strong fundamentals and positive momentum support growth outlook.

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
AI recommendation changes
Date Before After Reason
2026-05-16 02:45 Hold Buy Strong fundamentals, but recent volatility raises concerns.
2026-05-08 15:20 Hold Strong momentum and positive EPS surprise support growth outlook.
2026-05-04 02:37 Hold Buy Компания демонстрирует сильный рост выручки и положительные финансовые результаты, что указывает на хорошие перспективы. Низкий дивидендный доход и умеренный риск делают акцию привлекательной для долгосрочных инвестиций.
Analyst forecasts
Date Analyst Action Target Price Then
2026-06-09 10:24 Barclays Update — → 400 319.75
2026-04-27 12:36 Morgan Stanley Target Raised 285 → 315 306.39001
2026-04-27 10:04 Barclays Target Raised 275 → 310 306.16

Nothing yet